A Randomised, Double-blind, Double-dummy, Placebo-controlled, Multicentre, 6-way Crossover, Single-dose, Phase IIa Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Different Dry Powder Inhalation Formulations of AZD3199 Administered Via Single Inhalation Device Compared to AZD3199 Administered Via Turbuhaler™ Inhaler in Patients With Asthma
Phase of Trial: Phase II
Latest Information Update: 04 Mar 2013
At a glance
- Drugs AZD 3199 (Primary)
- Indications Asthma
- Focus Pharmacodynamics; Pharmacokinetics
- 15 Jun 2012 Actual patient number changed from 38 to 39 according to ClinicalTrials.gov.
- 20 Mar 2012 Status changed from active, no longer recruiting to completed as reported by EudraCT.
- 20 Mar 2012 Actual end date 27 Feb 2012 added as reported by EudraCT.